Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Capital Expenditures: 2015-2019

Historic Capital Expenditures for Outlook Therapeutics (OTLK) over the last 5 years, with Sep 2019 value amounting to $437,307.

  • Outlook Therapeutics' Capital Expenditures fell 148.38% to -$610,979 in Q3 2019 from the same period last year, while for Sep 2019 it was $437,307, marking a year-over-year decrease of 84.28%. This contributed to the annual value of $437,307 for FY2019, which is 84.28% down from last year.
  • Outlook Therapeutics' Capital Expenditures amounted to $437,307 in FY2019, which was down 84.28% from $2.8 million recorded in FY2018.
  • In the past 5 years, Outlook Therapeutics' Capital Expenditures ranged from a high of $8.8 million in FY2015 and a low of $292,086 during FY2017.
  • Its 3-year average for Capital Expenditures is $1.2 million, with a median of $437,307 in 2019.
  • Its Capital Expenditures has fluctuated over the past 5 years, first tumbled by 87.53% in 2016, then skyrocketed by 852.16% in 2018.
  • Outlook Therapeutics' Capital Expenditures (Yearly) stood at $8.8 million in 2015, then slumped by 87.53% to $1.1 million in 2016, then plummeted by 73.40% to $292,086 in 2017, then surged by 852.16% to $2.8 million in 2018, then tumbled by 84.28% to $437,307 in 2019.